These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27725309)

  • 1. Androgen receptor variation affects prostate cancer progression and drug resistance.
    McCrea E; Sissung TM; Price DK; Chau CH; Figg WD
    Pharmacol Res; 2016 Dec; 114():152-162. PubMed ID: 27725309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M; Antonarakis ES; Luo J
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular genetic mechanisms of drug resistance in prostate cancer].
    Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
    Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
    Sarwar M; Semenas J; Miftakhova R; Simoulis A; Robinson B; Gjörloff Wingren A; Mongan NP; Heery DM; Johnsson H; Abrahamsson PA; Dizeyi N; Luo J; Persson JL
    Oncotarget; 2016 Sep; 7(39):63065-63081. PubMed ID: 27588408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
    Biron E; Bédard F
    J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
    Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
    Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
    Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
    Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
    Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.